Sunflower Pharmaceutical Group Co.Ltd(002737) independent director
Independent opinions on matters related to the 14th meeting of the 4th board of directors
As an independent director of Sunflower Pharmaceutical Group Co.Ltd(002737) in accordance with the company law of the people’s Republic of China, the guiding opinions on the establishment of independent director system in listed companies, the self regulatory guidelines for listed companies No. 1 – standardized operation of listed companies on the main board, the stock listing rules of Shenzhen Stock exchange, the company charter and other relevant provisions With a realistic attitude, after careful and careful study, the independent opinions on the relevant proposals and matters considered at the 14th meeting of the Fourth Board of directors are as follows: I. independent opinions on the by election of independent directors of the company
After reviewing Mr. Shi Xianwang’s personal resume and other relevant materials, we believe that Mr. Shi Xianwang has relevant professional knowledge and ability, and has not found that he is not allowed to hold the position of independent director of the company as stipulated in the company law, the guidelines for self discipline supervision of listed companies No. 1 – standardized operation of listed companies on the main board, and the articles of association, As well as the situation that it is recognized as a market prohibited person by the CSRC or the prohibition has not been lifted. The qualification meets the relevant provisions of relevant laws, regulations and normative documents. The nomination procedure is legal and compliant. Agree to nominate Mr. Shi Xianwang as an independent director candidate of the Fourth Board of directors of the company and submit it to the general meeting of shareholders of the company for deliberation.
Independent director: Lin Ruichao, Li Huajie, Cui Lijing March 3, 2022
